1. Background {#sec89420}
=============

Bacteriophages are bacteria-specific viruses that infect and destroy their host bacteria. Bacteriophages are the most ubiquitous (total number estimated to be 10^30^-10^32^) known organisms on Earth. They are found everywhere and their isolation is not expensive ([@A17744R1]). Effective use of bacteriophages against bacteria was discovered by d'Herelle in 1915. In his studies he could observe clear plaques after treatment of bacteria with bacteriophages. Other researches have led to the therapeutic use of bacteriophages ([@A17744R2]). However, with advances of antibiotics these natural enemies of bacteria were put aside. Today, with dissemination of multi-drug resistant (MDR) bacteria we need to find new remedies to overcome MDR pathogens. Developing new antibiotics with new modes of action is critical in the battle against antibiotic-resistant bacteria, yet this solution has had a slow and expensive pathway over the past years. For example during 1998 to 2003 only two antibiotics with new modes of action were approved by the Food and Drug Administration (FDA) ([@A17744R1]).

Bacteriophages are accepted as natural antimicrobial agents to ﬁght bacterial infections in humans, animals or crops of agricultural importance ([@A17744R3]). Moreover, bacteriophages are easily accessed, cheap and safe for humans. On the other hand, resistance mechanisms to antibiotics and bacteriophages are different. Bacteria have different complex mechanisms against antibiotics, which are difficult to overcome; yet resistance to bacteriophages has not been commonly reported, and in case there is resistance, it will be via different mechanisms. This means that antibiotic resistant bacteria remain sensitive to bacteriophages. Thus they are the best choice for elimination of antibiotic resistant bacteria ([@A17744R1]). However, it is important to mention that successful use of bacteriophages for therapeutic purposes in humans requires more research. For example FDA approved a phase I clinical trial in 2008, which evaluated the safety of a phage cocktail to treat patients with infected venous leg ulcers ([@A17744R4]). *Escherichia coli* is a Gram-negative pathogen that causes a variety of diseases and can be present in wounds such as bed sore and foot ulcers of patients with diabetes. Local infections such as wounds are the first choice for the therapeutic application of bacteriophages. This study was done to evaluate the effectiveness of bacteriophages in removing antibiotic-resistant *E. coli*.

2. Objectives {#sec89421}
=============

This study aimed to evaluate the effectiveness of isolated phages against isolated resistant *E. coli* strains. The phages with broader host range in vitro were used in vivo in a mice model.

3. Patients and Methods {#sec89428}
=======================

3.1. Bacteria Cultivation and Identification {#sec89422}
--------------------------------------------

Different samples were collected from bed sore and foot ulcers of patients with diabetes. The samples were cultured on eosin--methylene blue (EMB) and blood agar media (Merck, Germany). The colonies were then purified and assessed by microscopic and culture methods and confirmed by standard biochemical tests such as the IMViC test.

3.2. Antibiotic Susceptibility Test {#sec89423}
-----------------------------------

Antibiogram of all isolated *E. coli* were ascertained using the Kirby Bauer disc diffusion method against ten antibiotics. All plates were incubated for 18-24 hours at 37°C and zone of inhibition was measured for each disc according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Ten antimicrobial agents belonging to eight different groups including amoxicillin (AMX), gentamicin (GM), nalidixic acid (NA), tetracycline (TE), azithromycin (AZM), colistin (CL), kanamycin (K), ciprofloxacin (CP), doxycycline (D), and cephalexin (CN) were used. All the test antibiotic discs were purchased from Padtan Teb Co.

3.3. Isolation and Purification of Bacteriophages for Clinical E. coli {#sec89424}
----------------------------------------------------------------------

The bacteriophages were isolated from environmental water samples. Some domestic wastewater and creek waters that flow in streets of Tabriz such as \"AjiChay\" river were used for sampling. After collecting 100 mL of water in sterile bottles, water samples were amplified by adding 50 mL of tryptic soy broth media (Merck, Germany) and inoculating host bacteria ([@A17744R5]). These water samples were incubated overnight at 37°C, followed by centrifugation after addition of chloroform. The supernatants were extracted as probable bacteriophage samples. The supernatants were exposed to the host bacteria by the double-layer agar method ([@A17744R6]). After overnight incubation at 37°C, plates were analyzed to observe plaques. Single plaques were separated and repeated culture in double-layer agar plates were done to extract single bacteriophages. Isolated bacteriophages were stored in SM buffer at 4°C.

3.4. Cross-Reactivity {#sec89425}
---------------------

In addition to the host microorganism used for isolation of each bacteriophage, activity of each bacteriophage against the other nine *E. coli* was examined by the double-layer agar method to determine potent broader-spectrum bacteriophages for therapeutic application.

3.5. Bacteriophage Titration {#sec89426}
----------------------------

For counting bacteriophages, dilutions were prepared by adding 900 µL of sterile water to each 100 µL of phage samples. Each dilution was cultured by the double layer method. At high dilutions whole surface of plates were lysed by bacteriophages. At lower dilutions, plaques were countable. The titer of a phage suspension was determined by counting the number of plaques that formed from a given volume of suspension, based on the fact that each plaque on a lawn of bacteria contains 10^6^ to 10^7^ phages ([@A17744R5]).

3.6. Animals {#sec89427}
------------

Thirty-five mice (25 - 30 gram each) were purchased from the faculty of new sciences of Tabriz University of Medical Sciences. They were randomly divided to five groups. A full thickness skin wound was made, by a surgical tool, on the mice's backs between their two ears. Group 1, which was the control group (C), did not receive anything. Group 2, the bacterial group (B), received *E. coli* M6 at a dose of 1.5 × 10^9^ CFU/mL. Group 3, the phage group (P), received only phage at a dose of 10^10^ PFU/mL. Group 4, the antibiotic therapy group (BA), received *E. coli* M6 at a dose of 1.5 × 10^9^ CFU/mL, and was treated by gentamicin after 24 hours and a repeated dose after 48 and 72 hours. Group 5, the phage therapy group (BP), received *E. coli* M6 at a dose of 1.5 × 10^9^ CFU/mL and after 24 hours, topically received a single dose of bacteriophage TPR7 with a dose of 10^10^ PFU/mL. Wound sampling was performed by a sterile swap every day after applying bacteria to the wound, and samples were cultured on EMB. After incubating for 24 hours, colonies were counted.

4. Results {#sec89429}
==========

In this study ten *E. coli* strains were successfully isolated from the clinical samples. They were called *E. coli* M1 to *E. coli* M10. Study of antibiotic resistance patterns showed high levels of resistance in *E. coli* isolates. The results showed that all strains were resistant to at least two antibiotics and six strains were resistant to six or seven antibiotics, indicating high levels of resistance. All strains were resistant to amoxicillin and azithromycin, yet sensitive to colistin. Except for two strains, the others were sensitive to gentamicin and kanamycin. Three strains were resistant to ciprofloxacin and five were resistant to tetracycline and doxycycline. Seven strains showed resistance to cephalexin and nalidixic acid. [Table 1](#tbl22841){ref-type="table"} illustrates the entire resistance patterns to antibiotics. At least one bacteriophage was isolated against each *E. coli* strain. They were called TPR1 to TPR10. Each of the bacteriophages lysed its host completely ([Figure 1](#fig17310){ref-type="fig"}). However, examination of their activity on other *E. coli* strains showed that each *E. coli* was sensitive to at least two phages in addition to its own specific phage ([Table 2](#tbl22842){ref-type="table"}).

The phage, TPR10, was effective against seven *E. coli* strains. Six *E. coli* strains were sensitive to TPR5 and TPR6. The phage, TPR4, was effective against half of the bacteria. Four bacteria were sensitive to TPR1, TPR8 and TPR9 while three of bacteria were sensitive to TPR2, TPR3 and TPR7. Furthermore, TPR10, TPR5 and TPR6 had broader host ranges and could be a good choice for phage therapy in clinical use for multiple infections. Comparison of the effectiveness of antibiotics and isolated bacteriophages on isolated bacteria is shown in [Table 3](#tbl22843){ref-type="table"}. The TPR7 isolate was selected to remove *E. coli* M6 in vivo because of its big and clear plaques. The other nine phages had different plaques according to size; some big and very small. Four mice in group B died on the third day. However, the other three mice were still infected by bacteria until the seventh day and they received serum because they were moribund. In group BA, there were no bacteria in their samples after the second day. Surprisingly in group BP results were similar to group BA, and there were no bacteria in their samples after the second day. The results of the sampling of the five groups are showed in [Figure 2](#fig17311){ref-type="fig"}. A single dose of phage could remove infection, while repeated doses of antibiotic were required for infection removal.

###### Antibiotic Resistant Patterns for the Clinical *Escherichia coli* Isolates ^[a](#fn20702){ref-type="table-fn"}^

                       *E. coli* M1   *E. coli* M2   *E. coli* M3   *E. coli* M4   *E. coli* M5   *E. coli* M6   *E. coli* M7   *E. coli* M8   *E. coli* M9   *E. coli* M10
  -------------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- ---------------
  **Amoxicillin**      R              R              R              R              R              R              R              R              R              R
  **Azithromycin**     R              R              R              R              R              R              R              R              R              R
  **Cephalexin**       R              S              R              S              R              R              R              R              R              S
  **Nalidixic Acid**   R              R              R              S              R              S              R              R              R              S
  **Doxycycline**      R              R              S              S              I              S              R              S              R              S
  **Tetracycline**     R              R              S              S              R              S              R              S              R              S
  **Ciprofloxacin**    R              S              R              S              R              S              S              S              S              S
  **Gentamicin**       S              S              R              S              S              S              R              S              S              S
  **Kanamycin**        S              R              I              S              R              S              S              S              S              S
  **Colistin**         S              S              S              S              S              S              S              S              S              S

^a^Abbreviations: I, intermediate; R, resistant; S, sensitive.

![Bacteriophage TPR6 Plaques on *E. coli* M6](jjm-08-02-17744-g001){#fig17310}

###### Cross-Reactivity of Isolated *E. coli*Strains and Bacteriophages

              *E. coli* M1   *E. coli* M2   *E. coli* M3   *E. coli* M4   *E. coli* M5   *E. coli* M6   *E. coli* M7   *E. coli* M8   *E. coli* M9   *E. coli* M10
  ----------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- ---------------
  **TPR1**    \+             \-             \+             \-             \+             \-             \-             \-             \+             \-
  **TPR2**    \-             \+             \+             \-             \-             \+             \-             \-             \-             \-
  **TPR3**    \+             \-             \+             \-             \-             \+             \-             \-             \+             \-
  **TPR4**    \-             \-             \-             \+             \+             \-             \+             \+             \+             \-
  **TPR5**    \-             \+             \+             \+             \+             \+             \-             \-             \-             \+
  **TPR6**    \-             \-             \+             \-             \+             \+             \+             \+             \+             \-
  **TPR7**    \+             \-             \-             \-             \-             \+             \+             \-             \-             \-
  **TPR8**    \+             \-             \-             \-             \-             \-             \+             \+             \+             \-
  **TPR9**    \+             \-             \-             \-             \-             \+             \-             \-             \+             \+
  **TPR10**   \+             \+             \-             \+             \-             \+             \+             \-             \+             \+

###### Resistance of Isolated *E. coli*Strains to Antibiotics and Susceptibility to Bacteriophages

                             *E. coli* M1   *E. coli* M2   *E. coli* M3   *E. coli* M4   *E. coli* M5   *E. coli* M6   *E. coli* M7   *E. coli* M8   *E. coli* M9   *E. coli* M10
  -------------------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- ---------------
  **Antibiotic resistant**   7              6              6              2              7              3              7              4              6              2
  **Phage sensitive**        6              3              5              3              4              6              5              4              6              3
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5. Discussion {#sec89430}
=============

Antibiotic resistant bacteria are increasingly found in different bacterial infections. Among bacterial infections, *E. coli* is present in many cases. Researches have shown high resistance to antibiotics by this bacterium. Momoh et al. ([@A17744R7]) studied the antibiogram types of *E. coli* isolated from suspected urinary tract infection samples and reported high resistance to the used antibiotics. Mubita et al. studied 83 *E. coli* isolates from cattle. They reported a high frequency of *E. coli* resistance to multiple antibiotics such as penicillin, erythromycin, co-trimoxazole and nitrofurantoin ([@A17744R8]). Thaker et al. ([@A17744R9]) studied antibiogram patterns of *E. coli* from raw milk samples and reported resistance to ampicillin, streptomycin, oxytetracycline and co-amoxiclav. Before the antibiotic era, some studies reported effective use of bacteriophages as an antimicrobial agent in animals and even in humans. Smith et al. ([@A17744R10]) successfully treated experimental *E. coli* infections in mice using phages. They also controlled experimental *E. coli* diarrhea in calves by means of bacteriophages. Their phage isolates effectively controlled the multiplication of that particular strain of *E. coli* in the small intestines of calves ([@A17744R11]).

Barrow et al. ([@A17744R12]) successfully used lytic bacteriophage for the control of experimental *E. coli* septicemia and meningitis in chickens and calves. Jamalludeen et al. ([@A17744R13]) evaluated bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic *E. coli* O149 infection in pigs. Their selected phages were effective in moderating the course of experimental O149:H10:F4 Enterotoxigenic *Escherichia coli* (ETEC) diarrhea in weaned pigs when given prophylactically or therapeutically. Other similar studies have been done in the past. However, with the emergence of antibiotics such research became rare. New studies for an alternative to antibiotics aimed to find methods for generation of bacteriophage cocktails with therapeutic potential, such as the research by Gu et al. ([@A17744R14]). A safety test of phage therapy was done in 2005, in which healthy human volunteers received *E. coli* bacteriophage T4 orally and the results showed safety of bacteriophages ([@A17744R15]). Our research supported past studies and showed that bacteriophages could be isolated and used effectively against antibiotic resistant clinical *E. coli* strains to remove these bacteria. Our research results showed different patterns of resistance to antibiotics and bacteriophages by bacteria.

The most resistant *E. coli* strains were resistant to seven antibiotics. However, *E. coli* M1, *E. coli* M5 and *E. coli* M7 were sensitive to six, four and five bacteriophages respectively. *E. coli* M4 and *E. coli* M10 which were the most sensitive bacteria to antibiotics were sensitive to three different bacteriophages. As the results show ([Table 3](#tbl22843){ref-type="table"}), the resistance pattern was different to antibiotics and bacteriophages. This maybe because the mechanisms of resistance against bacteriophages are different from those for resistance to antibiotics ([@A17744R3]). According to the results of this research, all ten isolated *E. coli* strains, which were resistant to several antibiotics, could be eliminated by bacteriophages, which are easily isolated from environmental water samples without the need for expensive procedures. Similar therapeutic effects of phages to antibiotics in vivo prove the fact that phages can be good alternatives for antibiotics to cure resistant infections.

This work was part of an MSc thesis from University of Tabriz. The authors appreciate the Emam Reza and Sina Hospital's staff for collecting the bacterial samples.

**Authors' Contributions:**Gholamreza Zarrini and Farzam Sheikhzadeh developed the original idea and the protocol. Naser Aghamohammadzadeh contributed to the isolation of bacterial strains and Rana Rahmani contributed to the experimental work.

**Funding/Support:**This study was supported by the University of Tabriz, Iran.
